The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for second-line therapy. Splenectomy continues to provide the highest cure rate (60-70% at 5+ years). Nonetheless, splenectomy is invasive, irreversible, associated with post-operative complications, and its outcome is currently unpredictable, leading some physicians and patients towards postponement and use of alternative approaches.
Introduction
Splenectomy has been the standard second-line treatment for adults with ITP for decades and remains the option that provides the highest cure rate. Careful choice of patients, widespread adoption of a laparoscopic approach, peri-operative thromboprophylaxis, and better approaches to prevent and mitigate sepsis have helped reduce morbidity, costs 1 and possibly mortality. 2 Concurrently, important advances have been made in understanding the pathogenesis of ITP accompanied by development of novel treatments, including anti-CD20 antibodies 3 and thrombopoietin receptor agonists (TPO-RAs). 4, 5 This has led to increased uncertainty as to when splenectomy is advisable as the standard next step. It has also become clear that some adults improve over time either spontaneously or as a result of treatment, leading some to recommend deferring surgery for one to several years. 6 Moreover, increased clinical awareness and use of laboratory testing now identifies concomitant illnesses in patients who otherwise meet diagnostic criteria for ITP ("cryptic" secondary ITP), including some, e.g. hepatitis C and common variable immune deficiency (CVID) , that mitigate against splenectomy.
It is our distinct impression that information of variable validity widely available on the
Internet has increased the number of patients who wish to avoid splenectomy. The introduction of new therapies and increased awareness of late remissions in ITP have resulted in physicians tending to avoid or defer splenectomy, which is increasingly viewed as the last resort, particularly in the United States and some European countries.
This is evidenced by a decrease in the rate of splenectomy for ITP from 50-60% in previously reported cohorts to 20-25% more recently.
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For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Two recent reviews of treatment for ITP have been published. 8, 9 The International Consensus document used both published studies and the accumulated experience of 22 international experts, somewhat akin to the process used to develop the initial ASH guidelines, though with less formal integration of expert opinion. 8 In contrast, the revised ASH guidelines focused on evidence-based medicine, with half of the writing group having expertise in trial-methodology and data-analysis, the remainder in ITP. 9 Both groups considered splenectomy, and both recommended it as a second-line therapy.
However, the International Consensus gave it equal place among a number of options, whereas the ASH guidelines gave splenectomy its highest grade of recommendation based on its curative effects and the extensive published experience. Additional guidelines that consider the role of splenectomy in second line treatment are summarized in Supplemental Table 1 .
This article on "How I Treat ITP" investigates the question: What is the optimal second line treatment for adults with ITP?
Splenectomy is considered in the context of the two most commonly employed, newer approaches to second line therapy: rituximab and TPO-RAs. Since no comparative evidence-based recommendations can be made, our focus is to consider and balance the potential benefits and relative contraindications of each option to help inform individualized care.
What is ITP?
ITP is an autoimmune disease characterized by isolated thrombocytopenia (platelet count <100,000/µl) resulting from accelerated clearance and destruction of antibodycoated platelets by tissue macrophages, predominantly in the spleen. 10 Anti-platelet antibodies also target antigens on megakaryocytes and pro-platelets, variably suppressing platelet production. 11, 12 Plasma thrombopoietin (TPO) is generally normal or only minimally elevated, primarily because of accelerated clearance via megakaryocytes and platelets.
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Activated cytotoxic CD8 positive T cells may contribute to thrombocytopenia in certain patients. 14 A potential underlying etiology giving rise to secondary ITP, such as infection with hepatitis C, human immunodeficiency virus (HIV) or Helicobacter pylori, and co-existence of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) or common variable immunodeficiency
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From (hypogammaglobulinemia, CVID) , is identified in approximately 20% of patients with immune thrombocytopenia. 15 Discovering an underlying cause is important since it may impact the efficacy and safety of splenectomy and other approaches (see below). 16, 17 Moreover, patients such as in the case example are often not thoroughly evaluated for secondary ITP and an underlying etiology may not be apparent on presentation.
Who should be treated?
Treatment is generally confined to patients who are bleeding or are perceived to be at significant risk of bleeding. The risk of bleeding is multi-factorial and its assessment is complex. For the most part, bleeding is related to a decreased platelet count, increasing age, co-morbidities (including their treatments), risk of trauma, and previous history of bleeding. 18 Although a platelet count of <30,000/µl is often used as a surrogate marker, 4, 5, 9, 19 lower (10-20,000/µl) or higher (50,000/µl) thresholds are pursued depending on the risk of bleeding, the presence of co morbidities, patient's lifestyle and risk of trauma, all of which need to be weighed against the likely benefits and the risk of treatment-related side effects. 20 Some therapies may improve health related quality of life (HRQoL), especially fatigue, although this issue is infrequently considered or invoked as a reason to treat. 21, 22 Comparative outcome studies are lacking here as well.
When should splenectomy be considered among second-line therapies?
The frequency of complete remission 23 after a course of first line therapy with corticosteroids ranges from 10-30% with daily oral prednisone 24 to as much as 60-80%
with high-dose, pulsed dexamethasone (HDD). 6, 25, 26 However, the latter remains to be confirmed in controlled trials and currently available evidence does not establish the superiority of HDD. 27 In the absence of such evidence, we do not routinely use multiple cycles of HDD to induce remission in patients who have failed a course of prednisone.
Patients may develop hemostatic platelet counts by one year (Figure 1 ) 6, 28 or occasionally after many years of severe disease without additional treatment. 29, 30 Accordingly, the International Consensus statement suggests deferring splenectomy until the chronic phase (> 12 months), if possible, unless an adequate count cannot be maintained with medical therapy, adverse reactions to medical alternatives develop, or there is compelling patient preference, e.g. because of life-style or employment. 8 For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
The management of patients who fail corticosteroids is challenging, as there have been no comparative trials of treatment options in this setting. The International Consensus report lists more than 10 second-line therapeutic options, including splenectomy, without indicating a preference. 8 The revised ASH guidelines recommend splenectomy (Grade-1B evidence) for patients who failed corticosteroid therapy while suggesting treatment with TPO-RAs and rituximab pre-splenectomy (Grade 2C evidence). 9 What follows is our analysis of the factors to be considered when choosing amongst the three most common options (Table 2 ; Figure 2 ). We recognize that other approaches, including watchful waiting may be appropriate in many patients. Also, other treatments widely used in some countries, such as dapsone and immunosuppressive agents, 8 are not commonly employed as second line treatments in our practice.
Splenectomy
Splenectomy has been employed for decades as the primary option in patients who require additional treatment after a course of corticosteroids.
What are the Pros of Splenectomy?
1-Splenectomy is "curative"
Splenectomy "cures" ITP by removing both the primary site of platelet destruction and an important site of anti-platelet antibody production in an uncertain but large proportion of patients. Platelet counts rise rapidly in 85% of patients. Relapses are encountered, especially in the first 2 years after surgery, but 60-65% of patients remain in clinical remission 5-10 years after splenectomy, an outcome unmatched by any other therapy (Figure 3) 
5-Splenectomy reduces cost
Prior to TPO-RA, the annual cost of treating severe chronic ITP was estimated to be $40,000 45 , although comprehensive cost-effectiveness studies are lacking in adults.
However, the cost of TPO-RAs ranges from $2500-$4000 per month, and each 4-infusion course of rituximab costs $10,000-$50,000, whereas the estimated total procedural cost of splenectomy is not more than $20,000. These cost estimates apply only to patients who respond. The societal cost of failed splenectomy includes the cost of surgical complications and subsequent therapy.
6-Pregnancy
Women with ITP who contemplate pregnancy may opt for splenectomy because most options for management of the maternal platelet count, including TPO-RA and rituximab, may not be safe for the fetus. 46, 47 However, women in remission post-splenectomy may relapse during pregnancy and the fetus/neonate may develop thrombocytopenia even if the splenectomized mother remains in remission.
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What are the Cons?
1-Removal of a "healthy" organ
Splenectomy is irreversible and consequently leads to the loss of its multiple hematologic and immunologic functions e.g. elimination of abnormal blood cells, cell particles and organisms from the blood and production of antibodies to blood-borne antigens. 
2-Unpredictability of response
The response to splenectomy cannot be predicted using readily available clinical criteria, e.g. previous response to steroids or IVIG, other than "older" age, which is ill-defined. 2 In a retrospective review of 111 In-labeled autologous platelet sequestration studies, the complete response rate after splenectomy was 87% (median 3.8 years follow up) in patients having predominantly splenic sequestration as opposed to 35% in those with "mixed" or hepatic sequestration (OR 5.39; 
3-Post-Splenectomy Mortality and Morbidity
Splenectomy is an invasive procedure associated with near-term complications primarily related to general anesthesia and surgery and long-term complications from loss of splenic functions.
a-Overall Mortality
The 30-day mortality and complication rates after laparoscopic splenectomy (0.2% and 9.6%) are reported to be lower than after open splenectomy (1% and 12.9% 7.9-143) compared to the general population. However, for patients with ITP, the difference in mortality during the first year after splenectomy was not significant when compared to the non-splenectomized cohort. Interestingly, after one year, the RR of death in the splenectomized ITP patients was significantly lower than in the matched ITP controls treated otherwise (RR 0.4; 95% CI 0.2-0.7). 52 However, the assessment period preceded the introduction of TPO-RAs and extensive use of rituximab; therefore data in the non-splenectomized ITP cohort was derived from an era when patients typically underwent prolonged exposure to high doses of corticosteroids and other immunosuppressives not widely used and/or no longer considered safe or appropriate in this setting.
b-Risk of infection
Since 1952, it has been evident that asplenic subjects are at increased risk of lifethreatening infections. 53 The Danish cohort study identified a 14-fold higher RR of sepsis in splenectomized ITP patients (n=269) during the first year after splenectomy and a 4-fold higher RR after 1 year compared to the general population. Importantly, compared to Repeated patient education is vital because the rarity of sepsis predisposes to noncompliance. Med-alert bracelets may be helpful. Guidelines for preventing sepsis and/or improving the outcome, when it occurs, vary but may include: a) repeat vaccination every 5-10 years or when antibody titers (especially to pneumococcus) fall; b) measurement of body temperature at the onset of any illness and urgent emergency room evaluation for a fever of 101 o F or higher with initiation of IV antibiotics such as ceftriaxone (absent allergy); and c) consideration of penicillin 250-500 milligrams twice a day for life (however, the incidence of pneumococcal penicillin resistance currently approaches 30%).
Exposure to infections with known worse outcomes in splenectomized patients, e.g. malaria and babesiosis, should be avoided if at all possible. Table 3 summarizes preand post-operative recommendations to minimize post splenectomy infectious complications.
c-Vascular complications
Splenectomy may increase morbidity from venous thromboembolism (VT) or atherosclerosis. Increased pro-coagulant derived microparticles, 55 platelet activation, disturbance and activation of the endothelium, altered lipid profiles and persistent thrombocytosis have been implicated in hypercoagulability in ITP.
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VT is reported to occur in up to 10% of patients with hematologic diseases undergoing splenectomy. 2, 38, 42, 56 The risk of VT is highest in the first year post-splenectomy, but even thereafter the rate of VT in splenectomized ITP was 2.7-fold (95% CI 1. especially with regard to selection, pre-and peri-operative management, laparoscopy by an experienced surgeon, and prophylaxis of and attention to sepsis and thrombosis.
On the other hand, data comparing splenectomized and non-splenectomized ITP patients, which suggest little difference in adverse outcomes (e.g. sepsis), were acquired in patients with extensive steroid exposure before the current era of TPO-RA and rituximab.
Furthermore, the long-term consequences of splenectomy remain ill defined. Delaying the decision for 12 months or more appears to lessen the need for surgery in a substantial proportion of patients. If this approach is adopted more widely, it may affect subsequent analyses, because restricting splenectomy to third-line "salvage" therapy will likely reduce not only the need but also the response rate.
Primary Alternative Therapeutic Options including Factors
Determining It provides long-term CR comparable to any therapy other than splenectomy. However, the long-term outcome after 4 standard-dose infusions is somewhat disappointing.
Additional benefits from co-administering dexamethasone and maintenance therapy appear promising and are under investigation
Thrombopoietin receptor agonists (TPO-RAs)
TPO-RAs are the only second-line therapy validated by randomized, controlled trials; however, thus far, the comparator arm was placebo. 4, 5, 22, 34, 35, 74 Two TPO-RAs, Romiplostim and Eltrombopag, are approved for use in over 80 countries. In the USA, Romiplostim is administered as subcutaneous weekly injections, which, at the time of this writing, must be administered by a health care provider. Eltrombopag is an oral agent given daily that must be taken at least 2 hours apart from ingestion of food and 4 hours apart from calcium-containing products (e.g. dairy) and supplemental iron.
a. Pros.
The reported response rates to TPO-RAs range from 59-88%; 22, 34, 35 b. Cons.
The major disadvantage of these agents compared to splenectomy and rituximab is the indefinite duration of treatment. As TPO-RAs are potentially life-long treatments, compliance may be a real issue. The current requirement for a healthcare professional to administer romiplostim and the alimentary requirements to ensure effective dosing of eltrombopag are cumbersome. TPO-RAs require at least 1-2 weeks to take effect (in responders) and therefore play at most a supplementary role in managing urgent conditions. Patients may experience mild-moderate headache, myalgias and gastrointestinal disturbances.
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Eltrombopag carries a black-box warning for hepatotoxicity. Neither should be used during pregnancy or lactation. "Rebound" thrombocytopenia occurs infrequently after abrupt discontinuation of TPO-RAs, which can be prevented by tapering the drugs and/or using rescue treatment, if needed. 22 An increase in bone marrow reticulin has been observed in several patients. 
c. Additional considerations:
Relapse occurs in a large majority of patients when treatment is interrupted. 74, 75, 79 An increase in regulatory T-cells (Tregs) is seen and a few patients appear to maintain adequate platelet counts off therapy. 80 In contrast to splenectomy and rituximab, TPO-RAs have only been in use for 7 years in trials and 3 years in general practice; hence experience in patients who were not eligible for inclusion on protocols is limited. 81 It is difficult to discern if there is an increase in the rate of VT compared with other successful interventions; it is important to take the underlying risk of arterial or venous thrombosis into consideration in patients with ITP and to consider use of aspirin in those at risk once the platelet count has entered a safe range, e.g.
>50,000/µL. Additional detailed analyses of toxicity have been reported in primary studies 4, 5, 22, 34, 35, 74, 75 and in reviews. 82 These agents are not approved for use presplenectomy in Europe unless surgery is contraindicated.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org1 5 d. Summary: TPO-RAs are highly effective before and after splenectomy, rituximab, and other agents. Toxicity appears limited, although surveys and studies are ongoing involving patients treated in the United States and elsewhere to better define complication rates (especially thrombosis and marrow fibrosis) in larger numbers of patients followed for longer times. There is no evidence at this time that there is any major difference in efficacy or toxicity between the two agents, although eltrombopag requires monitoring of liver function tests every 1-2 months, which may occasionally lead to at least temporary discontinuation, if abnormal. Anecdotal evidence suggests that infrequently one agent will be effective when the other is not. 
2-Co-morbidities:
Co-morbidities (e.g. serious cardiopulmonary disorders) increase the risk of general anesthesia and post-surgical complications. A higher rate of surgical complications and a lower response rate is reported in most studies of patients over 45- 
3-Restrictions imposed by health funding authorities
National health services in many European countries restrict the use of TPO-RA and rituximab. After application for permission, the cost may only be covered in splenectomized patients or if splenectomy is contraindicated, but the situation is liberalizing rapidly in some countries.
Deciding which option to pursue
Before considering treatment options, it is important to exclude inherited thrombocytopenias and secondary ITP that might not have been evident on presentation. At one end of the spectrum, splenectomy has the highest cure rate and may therefore be the preferred option for younger patients, who have the best response and lowest complication rates, engage in physically challenging sports or professions, are potentially non-compliant with protracted daily treatment, and who do not wish to continue to "deal 1 7
with" their ITP. Recommendations would be influenced by the results of platelet isotopic distribution studies (if confirmed and if available).
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At the other end of the spectrum, we try to avoid splenectomy in patients over 65-70 years of age (depending on their physical condition) not only because of higher complication rates, but also lower response rates. The same considerations apply to the very frail, those with significant surgical co-morbidities, history or risk of thrombosis, those with obligatory exposure to malaria or babesia, or who have secondary ITP.
Questions may be raised about post-splenectomy infection in teachers, veterinarians, healthcare providers, travelers to certain areas, or others with increased exposure to infectious conditions.
It is far more difficult to make recommendations for or against splenectomy to the majority of patients with ITP who do not meet these criteria and have no contraindications to surgery. Although splenectomy is recommended after the failure of steroids, there is an argument to be made for waiting one year or more after diagnosis before proceeding. 
Conclusions
The last decade has seen the introduction of new exciting suitable second-line medical approaches to manage adults with ITP. Each approach has unique benefits, limitations, and risks, and none have been subjected to head-to-head comparisons. Nor have quality of life or long-term comparative effectiveness analyses been performed to inform decisions. It is unlikely any comparative studies will hold interest for the pharmaceutical industry. Even consortia of major academic centers will have difficulty pursuing these studies because of the relatively low frequency of disease, cost and reimbursement issues, and the duration of studies needed to address critical concerns. Therefore, optimal treatment will continue to involve a personalized approach to therapy that combines the art of medicine with the science through close collaboration between patients and health-care providers for the foreseeable future.
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